Depolymerized holothurian glycosaminoglycan (dhg), a novel alternative anticoagulant for hemodialysis, is safe and effective in a dog renal failure model

Kidney International

Volumn 63, Issue 4, 2003, Pages 1548-1555

  Minamiguchi, Kazuhisa ^a,b   Kitazato, Keiko T ^a,b   Nagase, Hideki ^a,b   Sasaki, Eiji ^a,b   Ohwada, Katsuo ^a,b   Kitazato, Kenji ^a,b   Miyoshi, Kazuhisa ^b  

^a Microbial Chemistry Research Foundation   (Japan)

^b TAIHO PHARMACEUTICAL CO LTD   (Japan)

Author keywords

Anticoagulant; DHG; Dog with renal failure; Glycosaminoglycan; Hemodialysis

Indexed keywords

ANTICOAGULANT AGENT; CREATININE; HEMOGLOBIN; HEPARIN DERIVATIVE; HOLOTHURIAN GLYCOSAMINOGLYCAN; LOW MOLECULAR WEIGHT HEPARIN; NAFAMSTAT MESILATE; UNCLASSIFIED DRUG;

ANIMAL MODEL; ANTICOAGULATION; ARTERY LIGATION; ARTICLE; BLEEDING; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DEPOLYMERIZATION; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; EXTRACORPOREAL CIRCULATION; HEMODIALYSIS; KIDNEY FAILURE; MALE; MEASUREMENT; NONHUMAN; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; RENAL ARTERY; UREA NITROGEN BLOOD LEVEL;

EID: 0037378446     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1755.2003.00879.x     Document Type: Article

References (34)

1. SWARTZ RD: Hemorrhage during high-risk hemodialysis using controlled heparinization. Nephron 28:65-69, 1981
2. AGRESTI J, CONROY JD, OLSHAN A, et al: Heparin-free hemodialysis with cuprophan hollow fiber dialyzer by a frequent-saline-flush, high-blood-flow technique. Am Soc Artif Intern Organs 31:590-594, 1985
3. BERGREM H, LEIVESTAD T: Dialysis death and increased free fatty acids. Lancet 2:1160, 1978
4. KINUGASA E, KOJIMA H, TAMURA K, et al: Utility of FUT-175, an enzyme inhibitor, in hemodialysis - Its anticoagulative and anti-complement actions. J Jpn Soc Dial Ther 15:546, 1982
5. AKIZAWA T, SATO M, KITAOKA T, et al: The usefulness of the multienzyme inhibitor nafamostat mesilate in high-bleeding-risk hemodialysis. Proc Eur Dial Transplant Assoc 22:334-338, 1985
6. AKIZAWA T, KOSHIKAWA S, OTA K, et al: Nafamostat mesilate: A regional anticoagulant for hemodialysis in patients at high risk for bleeding. Nephron 64:376-381, 1993
7. LEU JG, CHIANG SS, LIN SM, et al: Low molecular weight heparin in hemodialysis patients with a bleeding tendency. Nephron 86:499-501, 2000
8. KOSHIKAWA S, AKIZAWA T, MIMURA N, et al: Effects of low molecular weight heparin as an anticoagulant for hemodialysis patients with bleeding risk. Multiinstitutional control study with low dose or regional heparinization. Clin Eval 19:541-571, 1991
9. AKIZAWA T, KITAOKA T, SATO M, et al: Comparative clinical trial of regional anticoagulation for hemodialysis. Am Soc Artif Intern Organs Trans 34:176-178, 1988
10. KITAGAWA H, CHANG H, FUJITA T: Hyperkalemia due to nafamostat mesilate. N Engl J Med 332:687, 1995
11. HIGUCHI N, YAMAZAKI H, KIKUCHI H, et al: Anaphylactoid reaction induced by a protease inhibitor, nafamostat mesilate, following nine administrations in a hemodialysis patient. Nephron 86:400-401, 2000
12. UEDA A, NAGASE S, MORITO N, et al: Anaphylactoid reaction induced by low-molecular-weight heparin in a hemodialysis patient. Nephron 87:93-94, 2001
13. GERLACH AT, PICKWORTH KK, SETH SK, et al: Enoxaparin and bleeding complications: A review in patients with and without renal insufficiency. Pharmacotherapy 20:771-775, 2000
14. YOSHIDA K, MINAMI Y, NEMOTO H, et al: Structure of DHG, a depolymerized glycosaminoglycan from sea cucumber, Stichopus japonicus. Tetrahedron Lett 33:4959-4962, 1992
15. NAGASE H, ENJOJI K, MINAMIGUCHI K, et al: Depolymerized holothurian glycosaminoglycan with novel anticoagulant actions: Antithrombin III- and heparin cofactor II-independent inhibition of factor X activation by factor IXa-factor VIIIa complex and heparin cofactor II-dependent inhibition of thrombin. Blood 85:1527-1534, 1995
16. NAGASE H, ENJOJI K, SHIMA M, et al: Effect of depolymerized holothurian glycosaminoglycan (DHG) on the activation of factor VIII and factor V by thrombin. J Biochem 119:63-69, 1996
17. NAGASE H, KITAZATO KT, SASAKI E, et al: Antithrombin III-independent effect of a new depolymerized holothurian glycosaminoglycan (DHG) on acute thromboembolism in mice. Thromb Haemost 77:399-402, 1997
18. KITAZATO K, KITAZATO KT, NAGASE H. et al: DHG, a new depolymerized holothurian glycosaminoglycan, exerts an antithrombotic effect with less bleeding than unfractionated or low-molecular-weight heparin, in rats. Thromb Res 84:111-120, 1996
19. MINAMIGUCHI K, KITAZATO KT, SASAKI E, et al: The anticoagulant and hemorrhagic effects of DHG, a new depolymerized holothurian glycosaminoglycan, on experimental hemodialysis in dogs. Thromb Haemost 77:1148-1153, 1997
20. MINAMIGUCHI K, NAGASE H, KITAZATO KT, et al: Interaction of a new depolymerized holothurian glycosaminoglycan with proteins in human plasma. Thromb Res 83:253-264, 1996
21. HASHIMOTO N, MORITA T, IWANAGA S: A method for systematic purification from bovine plasma of six vitamin-K-dependent coagulation factors: Prothrombin, factor X, factor IX, protein S, protein C, and protein Z. J Bioehem 97:1347-1355, 1985
22. OWEN WG, ESMON CT, JACKSON CM: The conversion of prothrombin to thrombin. J Biol Chem 249:594-605, 1974
23. CRADDOCK PR, FEHR J, DALMASSO AP, et al: Hemodialysis leukopenia. Pulmonary vascular leukostasis resulting from complement activation by dialyzer cellophane membranes. J Clin Invest 59:879-888, 1977
24. TOLLEFSEN DM, PETSKA CA, MONAFO WJ: Activation of heparin cofactor II by dermatan sulfate. J Biol Chem 258:6713-6716, 1983
25. LANE DA, RYAN K, IRELAND H, et al: Dermatan sulphate in hemodialysis. Lancet 339:334-335, 1992
26. PORTA R, PESCADOR R, NIADA R, et al: Profibrinolytic activities of chemically modified heparins with very low anticoagulant activities. Thromb Res 53:435-445, 1989
27. POPLAWSKI A, GLOWINSKI S: The effect of heparin on the plasma fibrinolytic activity. Acta Physiol Pol 25:39-42, 1974
28. POP AL-SAADY NM, LEATHAM EW, GUPTA S, et al: Monocyte expression of tissue factor and adhesion molecules: The link with accelerated coronary artery disease in patients with chronic renal failure. Heart 81:134-140, 1999
29. AMBUHL PM, WUTHRICH RP, KORTE W, et al: Plasma hypercoagulability in hemodialysis patients: Impact of dialysis and anticoagulation. Nephrol Dial Transplant 12:2355-2364, 1997
30. MATSUO T, KARIO K, NAKAO K, et al: Anticoagulation with nafamostat mesilate, a synthetic protease inhibitor, in hemodialysis patients with a bleeding risk. Haemostasis 23:135-141, 1993
31. BUSBY LT, WEYMAN A, RODGERS GM: Excessive anticoagulation in patients with mild renal insufficiency receiving long-term therapeutic enoxaparin. Am J Hematol 67:54-56, 2001
32. SMITH BS, GANDHI PJ: Pharmacokinetics and pharmacodynamics of low-molecular weight heparins and glycoprotein IIb/IIIa receptor antagonists in renal failure. J Thromb Thrombolysis 11:39-48, 2001
33. SASAKI E, MINAMIGUCHI K, KITAZATO KT, et al: Neutralization of DHG, a new depolymerized holothurian glycosaminoglycan, by protamine sulfate and platelet factor 4. Haemostasis 27:174-183, 1997
34. GRASSEGGER A, FRITSCH P, REIDER N, et al: Delayed-type hypersensitivity and cross-reactivity to heparins and danaparoid: A prospective study. Dermatol Surg 27:47-52, 2001